Roy Buchanan
Stock Analyst at JMP Securities
(1.33)
# 3,417
Out of 4,868 analysts
65
Total ratings
40.98%
Success rate
-15%
Average return
Main Sectors:
Stocks Rated by Roy Buchanan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PYPD PolyPid | Maintains: Market Outperform | $16 → $14 | $3.31 | +322.96% | 2 | Jun 17, 2025 | |
| ENTA Enanta Pharmaceuticals | Maintains: Market Outperform | $23 → $24 | $7.23 | +231.95% | 13 | Jun 3, 2025 | |
| CDTX Cidara Therapeutics | Reiterates: Market Outperform | $47 | $21.31 | +120.55% | 5 | Jun 2, 2025 | |
| CVAC CureVac | Reiterates: Market Outperform | $10 | $5.49 | +82.15% | 9 | May 28, 2025 | |
| DVAX Dynavax Technologies | Maintains: Market Outperform | $33 → $31 | $10.30 | +200.97% | 6 | May 7, 2025 | |
| ANTX AN2 Therapeutics | Maintains: Market Outperform | $5 → $2 | $1.10 | +81.82% | 9 | May 5, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Market Outperform | $18 | $1.95 | +823.08% | 3 | Mar 14, 2025 | |
| TPG TPG Inc. | Reiterates: Market Perform | n/a | $49.93 | - | 1 | Feb 13, 2025 | |
| ESPR Esperion Therapeutics | Reiterates: Market Outperform | $7 → $4 | $1.10 | +263.64% | 3 | Feb 11, 2025 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Market Outperform | $23 → $14 | $0.70 | +1,903.43% | 1 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $33 | $6.05 | +445.45% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $24 → $7 | $1.31 | +436.40% | 2 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $4 → $5 | $3.47 | +44.09% | 5 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $443 → $448 | $537.92 | -16.72% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $14 → $16 | $13.58 | +17.82% | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.90 | - | 2 | Feb 16, 2023 |
PolyPid
Jun 17, 2025
Maintains: Market Outperform
Price Target: $16 → $14
Current: $3.31
Upside: +322.96%
Enanta Pharmaceuticals
Jun 3, 2025
Maintains: Market Outperform
Price Target: $23 → $24
Current: $7.23
Upside: +231.95%
Cidara Therapeutics
Jun 2, 2025
Reiterates: Market Outperform
Price Target: $47
Current: $21.31
Upside: +120.55%
CureVac
May 28, 2025
Reiterates: Market Outperform
Price Target: $10
Current: $5.49
Upside: +82.15%
Dynavax Technologies
May 7, 2025
Maintains: Market Outperform
Price Target: $33 → $31
Current: $10.30
Upside: +200.97%
AN2 Therapeutics
May 5, 2025
Maintains: Market Outperform
Price Target: $5 → $2
Current: $1.10
Upside: +81.82%
Inovio Pharmaceuticals
Mar 14, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $1.95
Upside: +823.08%
TPG Inc.
Feb 13, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $49.93
Upside: -
Esperion Therapeutics
Feb 11, 2025
Reiterates: Market Outperform
Price Target: $7 → $4
Current: $1.10
Upside: +263.64%
Ironwood Pharmaceuticals
Jan 30, 2025
Maintains: Market Outperform
Price Target: $23 → $14
Current: $0.70
Upside: +1,903.43%
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $33
Current: $6.05
Upside: +445.45%
Nov 21, 2024
Maintains: Market Outperform
Price Target: $24 → $7
Current: $1.31
Upside: +436.40%
Aug 2, 2024
Maintains: Market Outperform
Price Target: $4 → $5
Current: $3.47
Upside: +44.09%
Mar 3, 2023
Maintains: Market Outperform
Price Target: $443 → $448
Current: $537.92
Upside: -16.72%
Mar 1, 2023
Maintains: Market Perform
Price Target: $14 → $16
Current: $13.58
Upside: +17.82%
Feb 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.90
Upside: -